Table 2 Clinical and demographic characteristics of the sample analyzed in the extension study of GSM treatment adherence during COVID-19 confinement
n (%) (n = 204) | |
|---|---|
Age | |
Median (IQR*) | 58 (54–60) |
Years of menopause | |
Median (IQR*) | 50 (49–52) |
Sexually active | |
Yes | 176 (86.3) |
No | 28 (13.7) |
Level of education | |
Basic-medium | 112 (54.9) |
University | 92 (45.1) |
Sexual activity during confinement | |
Decrease | 128 (62.7) |
Stable | 66 (32.3) |
Increase | 10 (4.9) |
Indicated treatments | |
Lubricants, moisturizers | 48 (23.5) |
Local estrogens | 120 (58.8) |
Prasterone | 20 (9.8) |
Ospemifene | 12 (5.9) |
MHT | 4 (2) |
Compliancea | |
Do you ever forget to take your medication? | 52 (25.5) |
Do you take the medication at the prescribed times? | 96 (47.1) |
If you feel well, do you not take it? | 52 (25.5) |
If it makes you feel worse, do you not take it? | 4 (2) |
Good complianceb | |
Yes | 56 (27.5) |
No | 148 (72.5) |
Reasons for poor compliance | |
Omission | 132 (66.7) |
Changes in sexual activity | 100 (49) |
Fear of going out to purchase it | 40 (19.6) |
Price | 36 (17.6) |
Efficacy | 20 (9.8) |
Other | 24 (11.8) |
COVID infection | |
Yes | 24 (11.8) |
No | 180 (88.2) |